Researchers announce breakthrough results for AMT-130, the first disease-modifying treatment for Huntington's disease, with ...

Topline data were announced from a pivotal phase 1/2 study evaluating AMT-130 in patients with Huntington disease.

An experimental gene therapy has slowed the progression of Huntington’s disease by 75 percent, according to results reported by the biotechnology company uniQure this week.

Qure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.

Viehbacher, “Biogen”) announced today that LEQEMBI ® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by ...

Introduction Therapeutic exercise has been used to improve cancer-related dysfunction. Recent studies suggest that exercise ...

Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by ...

LEQEMBI IQLIK, approved by the U.S. FDA in August 2025, is the first and only anti-amyloid treatment to offer an at-home injection after initial treatment of 18 months ...

CervoMed Inc. (NASDAQ:CRVO) shares surged 9% in premarket trading on Wednesday after the clinical-stage biopharmaceutical ...

Introduction Stroke is the second leading cause of death and disability creating a huge economic burden annually. Robot-assisted training (RT) is a promising therapy in stroke rehabilitation, but for ...

BlueRock Therapeutics reports positive 36-month results from phase I trial of bemdaneprocel for treating Parkinson’s disease: Berlin, Germany Wednesday, October 8, 2025, 18:00 H ...